Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$6.02 USD
+0.22 (3.79%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.00 -0.02 (-0.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Abeona Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 53 | 52 | 45 | 95 | 129 |
Receivables | 2 | 0 | 3 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 0 | 7 | 3 | 3 |
Total Current Assets | 56 | 53 | 55 | 98 | 132 |
Net Property & Equipment | 4 | 6 | 12 | 11 | 13 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 1 | 34 | 69 |
Deposits & Other Assets | 0 | 0 | 1 | 1 | 1 |
Total Assets | 64 | 64 | 80 | 151 | 223 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 4 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 4 | 6 | 3 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 0 | 5 | 32 | 28 |
Total Current Liabilities | 13 | 8 | 17 | 42 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 31 | 24 | 4 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 49 | 37 | 28 | 49 | 45 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 1 | 1 | 1 |
Capital Surplus | 764 | 722 | 706 | 672 | 664 |
Retained Earnings | -750 | -695 | -656 | -571 | -486 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 15 | 27 | 51 | 103 | 178 |
Total Liabilities & Shareholder's Equity | 64 | 64 | 80 | 151 | 223 |
Total Common Equity | 15 | 27 | 51 | 103 | 178 |
Shares Outstanding | 24.70 | 17.10 | 5.80 | 3.90 | 3.30 |
Book Value Per Share | 0.60 | 1.56 | 8.86 | 26.29 | 54.07 |
Fiscal Year End for Abeona Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 123 | 63 | 53 | 54 | 37 |
Receivables | 2 | 2 | 2 | 2 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 1 | 1 | 1 |
Total Current Assets | 126 | 67 | 56 | 57 | 44 |
Net Property & Equipment | 4 | 4 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 134 | 75 | 64 | 66 | 54 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 3 | 3 |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 3 | 6 | 4 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 5 | 5 | 0 | 0 |
Total Current Liabilities | 17 | 12 | 13 | 8 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 16 | 18 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 25 | 31 | 32 | 30 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 61 | 84 | 49 | 44 | 44 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 847 | 772 | 764 | 755 | 730 |
Retained Earnings | -774 | -781 | -750 | -733 | -721 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 73 | -9 | 15 | 22 | 9 |
Total Liabilities & Shareholder's Equity | 134 | 75 | 64 | 66 | 54 |
Total Common Equity | 73 | -9 | 15 | 22 | 9 |
Shares Outstanding | 40.90 | 27.50 | 24.70 | 24.70 | 21.40 |
Book Value Per Share | 1.79 | -0.32 | 0.60 | 0.89 | 0.44 |